GH stock sentiment todayGuardant Health, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
GH
Guardant Health, Inc.FDA approval of the Shield blood test for colorectal cancer has transformed GH from a niche oncology player into a mass-market diagnostic powerhouse.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GH. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the recent landmark FDA approval of Shield, the first blood-based CRC screening test to meet primary requirements for Medicare coverage. Bulls are focused on the massive TAM (Total Addressable Market) shift from late-stage monitoring to primary screening.
- ·FDA approval of Shield CRC blood test
- ·Potential inclusion in USPSTF guidelines
- ·Increasing adoption of Guardant360 in clinical settings
- ·Short-squeeze potential following regulatory wins
Financial
Revenue growth remains robust (25-30% YoY), though the company is still in the cash-burn phase as it scales the Shield launch. The balance sheet is stable enough to fund operations through the near-term commercial ramp-up.
- ·Q2 2024 Revenue: $177.2M (up 29% YoY)
- ·Gross Margin: ~60% (improving with volume)
- ·Cash & Equivalents: ~$1.1B
- ·Operating Loss: Narrowing but still significant
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Hollow hype — the story is loud but nobody with skin in the game is buying.
- ·Insiders sold a net $27.3M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Execution risk in highly competitive CRC screening market
- ·Reimbursement rate uncertainty for new tests
- ·Continued net losses delaying path to profitability
Peer temperature
How direct competitors stack up against GH right now.
- NEUTRALEXASExact Sciences Corp
COLDER — Shield poses a direct threat to Cologuard's market share, and EXAS faces higher saturation risks in the stool-based market.
See full analysis → - COLDILMNIllumina, Inc.
COLDER — Struggling with the messy divestiture of GRAIL and sluggish core sequencing machine demand compared to GH's diagnostic growth.
See full analysis → - HOTNTRANatera, Inc.
HOTTER — Delivering exceptional revenue beats and faster path to profitability within the MRD (Minimal Residual Disease) space.
See full analysis →
- GH-1.1%
- EXAS—
- ILMN+9.2%
- NTRA+19.5%
Analyst price target
Consensus average of 20 analysts · median 200.00
Source: StockAnalysis.com · updated 2026-09-08
AI-generated analysis for informational purposes only. Not financial advice.